Your session is about to expire
← Back to Search
Community Health Navigator Program for Chronic Conditions
N/A
Waitlist Available
Led By Kerry A McBrien, MD, MPH
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Poorly controlled diabetes (A1C > 9% on at least one occasion within the past year or labile)
Stage 3b or greater chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73m2 in past year)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 36 months
Awards & highlights
Study Summary
This trial is testing a program that uses community health navigators to help patients with multiple long-term health conditions get the care and resources they need.
Who is the study for?
This trial is for individuals with poorly controlled high blood pressure or diabetes, advanced kidney disease, heart failure, COPD or asthma with frequent visits, and ischemic heart disease. It's not suitable for those who can't consent, are in long-term care facilities, or if their health provider advises against it.Check my eligibility
What is being tested?
The ENCOMPASS study tests a Community Health Navigator Program where trained community members help patients manage multiple chronic conditions by guiding them through the healthcare system and connecting them to resources in Alberta, Canada.See study design
What are the potential side effects?
Since this intervention involves guidance and support rather than medical treatment, traditional side effects like you'd see with medications aren't expected. However, there may be indirect effects based on individual experiences with the program.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My diabetes is not well-managed, with an A1C over 9% in the past year.
Select...
My kidney function is reduced, with a filtration rate below 45 mL/min.
Select...
I have been diagnosed with heart disease.
Select...
I have been diagnosed with congestive heart failure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 36 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Acute care service use
Secondary outcome measures
Acute care costs
All-cause mortality rate
Anxiety symptoms
+22 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Community health navigator program for six months
Group II: ControlExperimental Treatment1 Intervention
Waitlist control: six-month waiting period followed by six months of community health navigator program
Find a Location
Who is running the clinical trial?
University of AlbertaOTHER
886 Previous Clinical Trials
384,717 Total Patients Enrolled
12 Trials studying Coronary Artery Disease
19,284 Patients Enrolled for Coronary Artery Disease
University of CalgaryLead Sponsor
791 Previous Clinical Trials
868,673 Total Patients Enrolled
11 Trials studying Coronary Artery Disease
10,735 Patients Enrolled for Coronary Artery Disease
Kerry A McBrien, MD, MPHPrincipal InvestigatorUniversity of Calgary
3 Previous Clinical Trials
455 Total Patients Enrolled
3 Trials studying Coronary Artery Disease
455 Patients Enrolled for Coronary Artery Disease
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My diabetes is not well-managed, with an A1C over 9% in the past year.You live in a long-term care facility.Your recent systolic blood pressure has been consistently high.My kidney function is reduced, with a filtration rate below 45 mL/min.I have been diagnosed with heart disease.I have been diagnosed with congestive heart failure.I am unable to understand and give consent for treatment.I have COPD or asthma and have seen a doctor for it at least twice last year.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this medical investigation currently accepting participants?
"Per the information on clinicaltrials.gov, recruitment for this medical trial is ongoing. It was originally posted on April 1st of 2021 and its most recent update occurred on May 19th of 2022."
Answered by AI
What is the current participant count for this clinical trial?
"Affirmative. According to the clinicaltrials.gov site, this research study is actively recruiting participants since its inception on April 1st 2021 and last amendment on May 19th 2022. The team seeks two hundred individuals from a single medical centre for the trial's duration."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger